- $31.36m
- $24.46m
- $7.53m
Brief: Evaxion Biotech A/S Registered Share Capital Increase Of DKK 1.6 MLn With Danish Business Authority
Evaxion Biotech A/S reports results for the quarter ended in January - Earnings Summary
Evaxion Biotech A/S expected to post a loss of 39 cents a share - Earnings Preview
Brief: Evaxion Biotech Q2 Basic EPS USD -0.12
Brief: Evaxion Biotech A/S Says Jesper Nissen Tendered Resignation As Interim CFO & COO
Ownership Agreement With Statens Serum Institut
Brief: Evaxion Receives Positive Feedback On Patent Application For AI-Based Novel Cancer Vaccine Target Identification Method
Brief: Evaxion Publishes Data Showing 67% Objective Response Rate In Metastatic Melanoma For AI-Designed Personalized Cancer Vaccine
Brief: Evaxion Expects Existing Cash, Cash Equivalents To Be Sufficient Into Q1 2025
Brief: Evaxion Biotech Q1 Basic EPS USD 0.03
Evaxion Biotech A/S expected to post a loss of 56 cents a share - Earnings Preview
Brief: Evaxion Receives Nasdaq Notification
Brief: Evaxion Biotech A/S Files For Offering Of Up To 19.45 Mln Ordinary Shares By Selling Shareholders
Brief: Evaxion Announces Phase 2 Clinical Trial Update
Brief: Evaxion To Develop Tailored Novel Cancer Vaccines Based Upon A New Untapped Source Of Ai-Discovered Targets
U.S. STOCKS ON THE MOVE-Fisker, Best Buy, NuStar Energy
Brief: Evaxion Announces Plan to Implement ADS Ratio Change
Evaxion Biotech A/S reports results for the quarter ended in September - Earnings Summary
Brief: Evaxion Announces Business Update And Third Quarter 2023 Financial Results